immunomodulary drug Setarud, which is composed of herbal extracts including Rosa canina, Urtica dioica and Tanacetum vulgare, supplemented with selenium exhibits anti-inflammatory and anti-oxidant properties. Therefor...immunomodulary drug Setarud, which is composed of herbal extracts including Rosa canina, Urtica dioica and Tanacetum vulgare, supplemented with selenium exhibits anti-inflammatory and anti-oxidant properties. Therefore, we hypothesized that Setarud will have a neuroprotective effect against ischemic cerebral injury. To validate this hypothesis, rats were intraperitoneally administered with 0.66 mL/kg Setarud for 30 minutes after middle cerebral artery occlusion. Triphenyltetrazolium chloride staining showed that Setarud could reduce cerebral infarct volume of rats subjected to cerebral ischemia. Transmission electron microscopy and hematoxylin-eosin staining results showed that Setarud could alleviate the degenerative changes in cortical neurons of rats with cerebral ischemia. The inclined plate test and prehensile test showed that Setarud could significantly improve the motor function of rats with cerebral ischemia. These findings suggest that Setarud shows neuroprotective effects against ischemic brain injury.展开更多
Based on our clinical experience,we formulated Huo Xue Tong Luo Tang(活血通络汤HXTL Decoction),a prescription for treatment of lacunar cerebral infarction.Most of the ingredients are those in the prescriptions of Di D...Based on our clinical experience,we formulated Huo Xue Tong Luo Tang(活血通络汤HXTL Decoction),a prescription for treatment of lacunar cerebral infarction.Most of the ingredients are those in the prescriptions of Di Dang Tang(抵当汤)and Gui Gan Long Mu Tang(桂甘龙牡汤)described in the book Treatise of Febrile Diseases(伤寒论)in accordance with the compatible theory of principal,assistant,adjuvant and guiding drugs for improving blood circulation,removing stasis,dispelling endogenous wind and phlegm,inducing resuscitation,removing obstruction in the channels,and balancing the yin and yang.展开更多
目的:对比CT与多模式MRI指导下缺血性脑卒中静脉溶栓治疗后出血转化的差异,明确多模式MRI指导溶栓的安全性。方法:回顾分析2009年6月-2011年10月期间接受静脉重组组织型纤溶酶原激活剂(rtPA)溶栓治疗的缺血性脑卒中患者资料,包括性别、...目的:对比CT与多模式MRI指导下缺血性脑卒中静脉溶栓治疗后出血转化的差异,明确多模式MRI指导溶栓的安全性。方法:回顾分析2009年6月-2011年10月期间接受静脉重组组织型纤溶酶原激活剂(rtPA)溶栓治疗的缺血性脑卒中患者资料,包括性别、年龄、既往史、溶栓时间、基线NIHSS、血压、血糖、电解质、凝血谱和心电图,以及溶栓后CT与MRI检查等,按照中国缺血性卒中亚型(CISS)标准予以病因分组。结果:共113例患者接受静脉rtPA治疗,平均年龄:(66±12)岁,男性74例,占65.5%,溶栓前美国国立卫生院卒中量表(National Institute of Health StrokeScale,NIHSS)评分12.4±6.5,发病至溶栓时间:(259.7±131.7)min;溶栓后24 h复查发现,34例(30.1%)出现溶栓后出血转化,其中9例(8%)为症状性出血。Logistic回归分析发现,多模式MRI指导下溶栓后的出血转化风险明显减少(OR=0.599,95%CI:0.373～0.962;P=0.034)。结论:多模式MRI指导溶栓相对于CT筛查,在静脉rtPA溶栓治疗后显示更低的出血转化率。展开更多
基金supported by a grant from the Vice Chancellor of Research at Kerman Medical University
文摘immunomodulary drug Setarud, which is composed of herbal extracts including Rosa canina, Urtica dioica and Tanacetum vulgare, supplemented with selenium exhibits anti-inflammatory and anti-oxidant properties. Therefore, we hypothesized that Setarud will have a neuroprotective effect against ischemic cerebral injury. To validate this hypothesis, rats were intraperitoneally administered with 0.66 mL/kg Setarud for 30 minutes after middle cerebral artery occlusion. Triphenyltetrazolium chloride staining showed that Setarud could reduce cerebral infarct volume of rats subjected to cerebral ischemia. Transmission electron microscopy and hematoxylin-eosin staining results showed that Setarud could alleviate the degenerative changes in cortical neurons of rats with cerebral ischemia. The inclined plate test and prehensile test showed that Setarud could significantly improve the motor function of rats with cerebral ischemia. These findings suggest that Setarud shows neuroprotective effects against ischemic brain injury.
文摘Based on our clinical experience,we formulated Huo Xue Tong Luo Tang(活血通络汤HXTL Decoction),a prescription for treatment of lacunar cerebral infarction.Most of the ingredients are those in the prescriptions of Di Dang Tang(抵当汤)and Gui Gan Long Mu Tang(桂甘龙牡汤)described in the book Treatise of Febrile Diseases(伤寒论)in accordance with the compatible theory of principal,assistant,adjuvant and guiding drugs for improving blood circulation,removing stasis,dispelling endogenous wind and phlegm,inducing resuscitation,removing obstruction in the channels,and balancing the yin and yang.
文摘目的:对比CT与多模式MRI指导下缺血性脑卒中静脉溶栓治疗后出血转化的差异,明确多模式MRI指导溶栓的安全性。方法:回顾分析2009年6月-2011年10月期间接受静脉重组组织型纤溶酶原激活剂(rtPA)溶栓治疗的缺血性脑卒中患者资料,包括性别、年龄、既往史、溶栓时间、基线NIHSS、血压、血糖、电解质、凝血谱和心电图,以及溶栓后CT与MRI检查等,按照中国缺血性卒中亚型(CISS)标准予以病因分组。结果:共113例患者接受静脉rtPA治疗,平均年龄:(66±12)岁,男性74例,占65.5%,溶栓前美国国立卫生院卒中量表(National Institute of Health StrokeScale,NIHSS)评分12.4±6.5,发病至溶栓时间:(259.7±131.7)min;溶栓后24 h复查发现,34例(30.1%)出现溶栓后出血转化,其中9例(8%)为症状性出血。Logistic回归分析发现,多模式MRI指导下溶栓后的出血转化风险明显减少(OR=0.599,95%CI:0.373～0.962;P=0.034)。结论:多模式MRI指导溶栓相对于CT筛查,在静脉rtPA溶栓治疗后显示更低的出血转化率。
